Page 5 - Bio Media Contact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesVikram baliSteering committeeAmerican heart associationDrug administrationBridgebio pharma incEuropean society of cardiology congressExchange commissionBio pharma incSecurities exchangeUniversity of south carolinaTransthyretin amyloidosis cardiomyopathyWin ratioHazard ratioNew drug applicationBio pharma

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria - Rapid and sustained impact of.

United statesVikram baliScott adlerRachel gafniPamerican society for boneMineral researchEuropean unionNational institutes of healthSecurities exchangeGeisinger health systemCraniofacial researchBridgebio pharma incDrug administrationEndocrine society meetingBio pharmaNew england journal

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate.

United kingdomSouth carolinaUnited statesTamy harperDouglas sprouleVikram baliVirginia commonwealth universityMl bio solutionsWorld muscle societyDrug administrationBridgebio pharma incBio pharma incSecurities exchangeNorth star assessmentAccelerated approvalBio pharma

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

- The primary endpoint was met with a highly statistically significant p-value ; this primary endpoint result consistently favored acoramidis treatment across key subgroups, including across both.

Vikram baliJulian gillmoreSecurities exchangeEuropean society of cardiology congressExchange commissionGlobenewswire incDrug administrationBridgebio pharma incKansas city cardiomyopathy questionnaireNew drug applicationBio pharmaHot lineCardiology congressSecurities actSecurities exchange actExchange act

BridgeBio presents detailed positive results from Phase 3

- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently.

Vikram baliJulian gillmoreBio pharma incSecurities exchangeEuropean society of cardiology congressExchange commissionDrug administrationBridgebio pharma incWin ratioKansas city cardiomyopathy questionnaireNew drug applicationBio pharmaHot lineEuropean societyCardiology congressBridgebio pharma